SUCLG2 and neoplasm: Xenografts of A549‐SUCLG2 cells displayed a reduced tumor weight and volume compared with those of A549‐SUCLG2WT (Figure 8K–M), and the IHC results demonstrated that the expression of Ki67 was decreased and that of TTF1 was increased in SUCLG2K93R mutant tumors compared with SUCLG2WT tumors (Figure 8N).